Since December 16, 2022, Moderna Pharmaceuticals has filed an application with Invima for the “Emergency Use Health Authorization (ASUE)” of its biological SPIKEVAX BIVALENT. These bivalent vaccines are the most technologically developed to date and generate greater protection against the most contagious strains, lineages and variants of the coronavirus.
Invima, in a resolution that was signed on June 30, endorsed the application of this biological and prioritized population groups to access this dose of the vaccine. SIKEVAX was authorized “in population groups at high risk of complications of 18 years of age and older who have previously received at least the first vaccination against COVID-19,” dictates the Invima resolution.
In addition, for the administration of the biological (which must be intramuscularly, the dose is 0.5 mL) there must be an interval of 6 months, compared to the application of the last vaccine in the regular immunization schedule against COVID-19. . For now, Invima indicates that the safety and efficacy of the vaccine in children under 18 years of age have not been established.
Caracol Radio was able to establish that in addition to Moderna, in the next few hours the resolution that will authorize the bivalent vaccine from the pharmaceutical company Pfizer will be published, it would also be given under the mechanism (ASUE) and in the next few hours the indications for the application of this biological in the national territory.
In order for Colombians to be vaccinated with these bivalent vaccines, the Ministry of Health must issue an administrative act in which the application of the doses is regulated. The health portfolio had recently issued a regulation that allowed people with comorbidities to receive a fifth dose. An update of this administrative act could expedite the start of vaccination in Colombia with bivalent vaccines.
2023-07-06 18:57:34
#Moderna #Pfizer #receive #authorization #apply #bivalent #COVID19 #vaccines #Colombia
